Endocrine treatment of prostate cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 92, Issue 4, 2004, Pages 287-295

  Tammela, Teuvo ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adverse effects; Antiandrogens; GnRH agonists; GnRH antagonists; Oestrogens; Timing of treatment

Indexed keywords

AMINO ACID DERIVATIVE; ANTIANDROGEN; BICALUTAMIDE; BUSERELIN; ESTROGEN; FLUTAMIDE; GONADORELIN; GOSERELIN; LEUPRORELIN; NILUTAMIDE;

ALCOHOL INTOLERANCE; ANDROGEN DEFICIENCY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DATA ANALYSIS; DECISION MAKING; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG EFFICACY; EARLY DIAGNOSIS; FEMINIZATION; GYNECOMASTIA; HEART FAILURE; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MEDICAL RECORD; NAUSEA; ORCHIECTOMY; OSTEOPOROSIS; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SIDE EFFECT; THROMBOEMBOLISM; TREATMENT OUTCOME; VISUAL DISORDER;

EID: 12344254089     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.10.005     Document Type: Article

References (77)

1. C. Huggins, and C.V. Hodges Studies on prostate cancer: I. The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res. 1 1941 293 297
2. L. Klotz Hormone therapy for patients with prostate carcinoma Cancer 88 2000 3009 3014
3. N. Kyprianou, and J.T. Isaacs Quantal relationship between prosttaic dihydrotestosterone and prostatic cell content: critical threshold concept Prostate 11 1987 41 50
4. C. Palmberg, P. Koivisto, T. Viaskorpi, and T.L.J. Tammela PSA decline is an independent prognostic marker in hormonally treated prostate cancer Eur. Urol. 36 1999 191 196
5. D. Scherr, P.W. Swindle, and P.T. Scardino National comprehensive cancer network guidelines for the management of prostate cancer Urology 61 Suppl. 2A 2003 14 24
6. P.M. Conn, and F.W. Crowley Gonadotropin-releasing hormone and its analogs Annu. Rev. Med. 45 1994 391 405
7. Å. Tieva, A. Bergh, and J.-E. Damber The clinical implications of the difference between castration, gonadotropin releasing-hormone (GnRH) antagonists and agonist treatment on the morphology and expression of GnRH receptors in the rat ventral prostate BJU Int. 91 2003 227 233
8. J. Seidenfeld, D.J. Samson, V. Hasselblad, N. Aronson, P.C. Albertsen, C.L. Bennett, and T.J. Wilt Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann. Intern. Med. 132 2000 566 577
9. G.J. Bubley Is the flare phenomenon clinically significant? Urology 58 2001 5 9
10. F. Labrie Intracrinology Mol. Cell. Endocrinol. 78 1991 C113 C118
11. C.R. Smart The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiologuý, and end results program Cancer 80 1997 1835 1844
12. Prostate Cancer Trialists' Collaborative Group Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials Lancet 355 2000 1491 1498
13. D.J. Samson, J. Seidenfeld, B. Schmitt, V. Hasselblad, P.C. Albertsen, C.L. Bennett, T.J. Wilt, and N. Aronson Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma Cancer 95 2002 361 376
14. M.A. Eisenberger, B.A. Blumstein, E.D. Crawford, G. Miller, D.G. McLeod, P.J. Loehrer, G. Wilding, K. Sears, D.J. Culkin, I.M. Thompson Jr., A.J. Bueschen, and B.A. Lowe Bilateral orchiectomy with or without flutamide for metastatic prostate cancer N. Engl. J. Med. 339 1998 1036 1042
15. M. Kovacs, A.V. Schally, B. Csernus, and Z. Rekasi Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LH-RH by counteracting the stimulatory effect of endogenous LH-RH Proc. Natl. Acad. Sci. U.S.A. 98 2001 1829 1834
16. G. Halmos, J.M. Arencibia, A.V. Schally, R. Davis, and D.G. Bostwick High incidence of receptors for luteinizing hormone-releasing (LHRH) and LHRH receptor gene expression in human prostate cancers J. Urol. 163 2000 623 629
17. The Veterans Administration Co-operative Urological Research Group Treatment and survival of patients with cancer of the prostate Surg. Gynecol. Obstet. 124 1967 1011 1017
18. P. Herinkson, M. Blombäck, A. Eriksson, R. Stege, and K. Carlström Effect of parenteral oestrogen on the regulation system in patients with prostatic carcinoma Br. J. Urol. 65 1990 282 285
19. A.K. Mikkola, M.L. Ruutu, J.L. Aro, S.A. Rannikko, J.O. Salo Finnprostate Group Parenteral polyestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer, Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study Br. J. Urol. 82 1998 63 68
20. P.O. Hedlund, M. Ala-Opas, E. Brekkan, J.E. Damber, L. Damber, I. Hagerman, S. Haukaas, P. Henriksson, P. Iversen, Å. Pousette, F. Rasmussen, J. Salo, S. Vaage, E. Varenhorst The SPCG-5 Study Group Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostate cancer Scand. J. Urol. Nephrol. 36 2002 405 413
21. P.O. Hedlund Side effects of endocrine treatment and their mechanisms: castration, antiandrogens and estrogens Prostate Suppl. 10 2000 32 37
22. Karling p, M. Hammar, and E. Varenhorst Prevalence and duration of hot flushes after surgical and medical castration in men with prostatic carcinoma J. Urol. 152 1994 1170 1173
23. A.-C. Spetz, M. Hammar, B. Lindberg, A. Spånberg, E. Varehorst The Scandinavian Prostatic Cancer Group-5 Trial Study Group Prospective evaluation of hot flushes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate J. Urol. 166 2001 517 520
24. S.B. Strum, J.E. McDermed, M.C. Scholz, H. Johnson, and G. Tisman Anaemia associated with androgen deprivation in patients with prostatic cancer receiving combined hormone blockade Br. J. Urol. 79 1997 933 941
25. N.W. Clarke, J. McClure, and N.J. George Preferential preservation of bone mineral mineralization by LHRH agonists in the treatment of metastatic prostate cancer Eur. Urol. 19 1991 114 117
26. H.W. Daniell Osteoporosis after orchiectomy for prostate cancer J. Urol. 157 1997 439 444
27. J. Morote, E. Martinez, E. Trilla, S. Esquena, J.M. Abascal, G. Encabo, and J. Reventos Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment Eur. Urol. 44 2003 661 665
28. M.F. Townsend, S.W. Sanders, and R.O. Northway Bone fractures associated with luteinizing hormone-releasing hormone agonist used in the treatment of prostate cancer Cancer 79 1997 545 550
29. M. Smith Osteoporosis during androgen deprivation therapy for prostate cancer Urology 60 Suppl. 3A 2002 79 86
30. H.W. Daniell Osteoporosis due to androgen deprivation in men with prostate cancer Urology 58 Suppl. 2A 2001 101 107
31. C. Higano, C. Stephens, and P. Nelson Prospective serial measurements of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen suppression Proc. Am. Soc. Clin. Oncol. Suppl. 18 1999 314a (abstract)
32. E. Varenhorst, L. Wallentin, and K. Carlström The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate Scand. J. Urol. Nephrol. 16 1982 31 36
33. H.J. de Voogt The position of cyproterone acetate (CPA), a steroidal anti-androgen, in the treatment of prostate cancer Prostate Suppl. 4 1992 91 95
34. J.L. Gomez, A. Dupont, L. Cusan, M. Tremblay, R. Suburu, M. Lemay, and F. Labrie Incidence of liver toxicity associated with the use of flutamide in prostatic cancer patients Am. J. Med. 92 1992 465 470
35. L. Boccon-Gibod Are non-steroidal anti-androgens appropriate as monotherapy in advanced prostate cancer? Eur. Urol. 33 1998 159 164
36. L. Boccon-Gibod Non-steroidal antiandrogen monotherapy of advanced prostate cancer - a reasonable option? Curr. Opin. Urol. 7 1997 268 272
37. F. Boccardo, A. Rubagotti, and M. Barichello Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of Italian Prostate Cancer Project study J. Clin. Oncol. 17 1999 2027 2938
38. P. Iversen, C.J. Tyrrell, A.V. Kaisary, J.B. Anderson, H. van Poppel, T.L.J. Tammela, M. Chamberlein, K. Carroll, and I. Melezinik Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years followup J. Urol. 164 2000 1579 1582
39. W.A. See, M.P. Wirth, D.G. McLeod, P. Iversen, I. Klimberg, D. Gleason, G. Chodak, J. Montie, C. Tyrrell, D.M.A. Wallace, K.P.J. Delaere, S. Vaage, T.L.J. Tammela, O. Lukkarinen, B.-E. Persson, K. Carroll, and G.J.C.M. Kolvenbag Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program J. Urol. 168 2002 429 435
40. J. Verhelst, L. Denis, P. van Vliet, H. van Poppel, J. Braeckman, P. van Cangh, J. Mattelaer, D. D'Hulster, and C. Mahler Endocrine profiles during administration of the new non-steroidal anti-androgen Casodex in prostate cancer Clin. Endocrinol. (Oxf) 41 1994 525 530
41. C.J. Tyrrell, A.V. Kaisary, P. Iversen, J.B. Anderson, L. Baert, T. Tammela, M. Chamberlein, and A. Wrbster Blackledge G. TI: A randomised comparison of "Casodex" (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer SO: Eur. Urol. 33 1998 447 456
42. P. Iversen, T.L.J. Tammela, S. Vaage, O. Lukkarinen, P. Lodding, T. Bull-Njaa, J. Viitanen, P. Hoisaeter, P. Lundmo, F. Rasmussen, J.E. Johansson, B.E. Persson, K. Carrol Scandinavian Prostate Cancer Group (SPCG) A randomised comparison of bicalutamide ("Casodex", 150 mg versus placebo as immediate therapy as alone or as adjuvant to standard care for early non-metastatic prostate cancer. First report from the Scandinavian Prostatic Cancer Group Study N. 6 Eur. Urol. 42 2002 204 211
43. C.J. Tyrrell Gynaecomastia: aetiology and treatment options Prostate Cancer Prostatic Dis. 2 1999 167 171
44. N. Bruchovsky, P.S. Rennie, A.J. Coldman, S.L. Goldenberg, M. To, and D. Lawason Effetcts of adrogen withdrawal on the stem cell composition of the Shionogi carcinoma Cancer Res. 50 1990 2275 2282
45. L. Boccon-Gibod, A. Bertaccini, A.V. Bono, B. Dev Sarmah, W. Höltl, N. Mottet, U. Tunn, and N. Zamboglou Management of locally advanced prostate cancer: a European consensus IJCP 57 2003 187 194
46. W. Albrecht, L. Collette, C. Fava, O.B. Kariakine, P. Whelan, U.E. Studer, T.M. De Reijke, and L.A. Rea Intermittent maximal androgen blockade in patients with metastatic prostatic cancer: an EORTC feasibility study Eur. Urol. 44 2003 505 511
47. M.P. Wirth, and M. Froehner Value of endocrine therapy for early and locally advanced prostate cancer Drugs Aging 20 2003 115 124
48. M.S. Soloway, K. Pareek, R. Sharif, Z. Wajsman, D. McLeod, and D.P. Wood Jr. Puras-Baez, Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results J. Urol. 167 2002 112 116
49. M.E. Gleave, S.E. La Bianca, S.L. Goldenberg, E.C. Jones, N. Bruchovsky, and L.D. Sullivan Long-term neoadjuvant therapy prior to radical prostatectomy: evaluation of risk for biochemical recurrence at 5-year follow-up Urology 56 2000 289 294
50. C.J. Tyrrell Adjuvant and neoadjuvant hormonal therapy for prostate cancer Eur. Urol. 36 1999 549 558
51. M.J. Scolieri, A. Altman, and M.I. Resnick Neoadjuvant hormonal ablative therapy before radical. Radical Prostatectomy: a review. Is it indicated? J. Urol. 164 2000 1465 1472
52. H. Zincke, W. Lau, E. Bergstrahl, and M.L. Blute Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer J. Urol. 166 2001 2208 2215
53. J.G. Trapasso, J.B. deKernion, R.B. Smith, and F. Dorey The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy J. Urol. 152 1994 1821 1825
54. E.M. Messing, J. Manola, M. Sarosdy, G. Wilding, E.D. Crawford, and D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N. Eng. J. Med. 341 1999 1781 1788
55. C.R. Pound, A.W. Partin, J.I. Epstein, and P.C. Walsh Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control Urol. Clin. North. Am. 24 1997 395 406
56. M. Roach III Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer Eur. Urol. 32 1997 48 54
57. J.S. Rasey, W.J. Koh, M.L. Evans, L.M. Peterson, T.K. Lewellen, M.M. Graham, and K.A. Krohn Quantifying regional hypoxia in human tumors with positron emission tomography of (18F) fluoromisonidazole: a pretherapy study of 37 patients Int. J. Radiot. Oncol. Biol. Phys. 36 1996 417 428
58. A. Pollack, D.L. Joon, C.S. Wu, C. Sikes, M. Hasegawa, N.H. Terry, R.A. White, G.K. Zagaras, and M.L. Meistrich Quiescence in R3327-G rat prostate tumors after androgen ablation Cancer Res. 15 1997 2493 2500
59. A.V. D'Amico Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer Urology 60 2002 32 38
60. M.J. Zelefsky, and Harrison Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy Urology 49 Suppl. 3A 1997 38 45
61. K.R. Blank, R. Whittington, B. Arjomandy, A.J. Wein, G. Broderick, J. Staley, and S.B. Malkowicz Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity Cancer J. Sci. Am. 5 1999 370 373
62. R. Kucway, F. Vicini, R. Huang, J. Stromberg, J. Gonzalez, and A. Martinez Prostate volume reduction with antiandrogen deprivation therapy before interstitial brachytherapy J. Urol. 167 2002 2443 2447
63. M. Bolla, D. Gonzalez, P. Warde, J.B. Dubois, R.O. Mirimanoff, G. Storme, J. Bernier, A. Kuten, C. Sternberg, T. Gil, L. Collette, and M. Pierart Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N. Engl. J. Med. 337 1997 295 300
64. C.A. Lawton, K. Winter, A. Murray, M. Machtay, J.B. Mesic, G.E. Hanks, C.T. Coughlin, and M.V. Pilepich Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate Int. J. Radiat. Oncol. Biol. Phys. 49 2001 937 946
65. M.V. Pilepich, K. Winter, M.J. John, J.B. Mesic, W. Sause, C. Lawton, M. Machtay, and Grignon Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate Int. J. Radiat. Oncol. Biol. Phys. 50 2001 1243 1252
66. A. Bayley, and M.K. Gospodarowicz Radiotherapy for T3 prostate cancer Curr. Urol. Report 4 2003 205 210
67. P.C. Walsh, T.L. DeWeese, and M.A. Eisenberger A structured debate: immediate versus deferred androgen suppression in prostate cancer - evidence for deferred treatment J. Urol. 2001 508 515
68. The Medical Research Council Prostate Cancer Working Party Investigators Group Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial Br. J. Urol. 79 1997 235 246
69. T. Granfors, H. Modig, J.E. Damber, and R. Tomic Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomised study J. Urol. 159 1998 2030 2034
70. C. Palmberg, P. Koivisto, L. Kakkola, T.L.J. Tammela, O.P. Kallioniemi, and T. Visakorpi Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer J. Urol. 164 2000 1992 1997
71. O. Kucuk, E. Fisher, C.M. Moinpour, D. Coleman, M.H. Hussain, A.O. Sartor, G.S. Chatta, B.A. Lowe, M.A. Eisenberger, and E.D. Crawford Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235) Urology 58 2001 53 58
72. T. Visakorpi, E. Hyytinen, P. Koivisto, M. Tanner, R. Keinänen, C. Palmberg, A. Palotie, T. Tammela, J. Isola, and O.P. Kallioniemi In vivo amplification of the androgen receptor gene and progression of human prostate cancer Nat. Genet. 9 1995 401 406
73. P. Koivisto, J. Kononen, C. Palmberg, T. Tammela, E. Hyytinen, J. Isola, J. Trapman, K. Cleutjens, A. Noordzij, T. Visakorpi, and O.P. Kallioniemi Cancer Res. 1997 314 319
74. E.J. Small, and N.J. Vogelzang Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm (review) J. Clin. Oncol. 15 1997 382 388
75. H.I. Scher, and W.K. Kelly Flutamide withdrawal syndrome: its impact on clinical trial in hormone-refractory prostate cancer J. Clin. Oncol. 11 1993 1566 1572
76. C.J. Tyrrell Controversies in the management of advanced prostate cancer Br. J. Cancer 79 1999 146 155
77. E.J. Small, and P.R. Carrol Prostate-specific antigen decline after casodex withdrawal: evidence for antiandrogen withdrawal syndrome Urology 4 1994 408 410